In Episode 22 of the Biopharma EHS podcast, Dean M. Calhoun, CIH, President of Affygility Solutions, interviews Ms. Stephanie Wilkins, President of PharmaConsult US, regarding the topic of Risk-MaPP, ADEs and PDEs: Their importance to multi-product pharmaceutical manufacturing facilities. The interview is approximately 22-minutes long and is available on Affygility Solutions’ Facebook page, Soundcloud, iTunes, and now on Stitcher. You can also listen via the audio player below:
If you like what you heard, please share it,and if you need either an occupational exposure limit (OEL) or acceptable daily exposure (ADE) value for your active pharmaceutical ingredient, check out the OEL Fastrac catalog for a complete listing of all our occupational exposure limit monographs with ADEs. Purchase online with immediate instant download!
Potent Compound Safety Training Made Easy!
Affygility Solutions is pleased to announce that its Introduction to Potent Compound Safety training video is now available in streaming format for only $59 on a pay-per-view basis. This price includes two views. In this 29-minute streaming video, the following topics are covered:
- The definition of a potent compound;
- Why you should care about potent compound safety;
- The basic principles of occupational exposure control banding;
- Controlling occupational exposures to potent compounds; and
- Several cases studies where occupational exposures to potent compounds have occurred, causing adverse health effects in employees.
This video is perfect for safety meetings or for new employee orientation. It is designed for those employees needing a basic knowledge of potent compound safety. No special hardware or software to install. It will even be viewable on your iPhone (4 or higher) or iPad. To purchase via credit card and begin streaming, click on the “Add to Cart” button below.
Dimethyl Fumarate (DMF) requires advance handling precautions in an occupational exposure setting.
IMPORTANT: Dimethyl fumarate (DMF) is a severe dermal sensitizer and advance handling precautions need to be taken before handling this compound in an occupational exposure setting. In addition, dimethyl fumarate is known to sublimate (going from the solid to gaseous phase without turning into a liquid). This has implications for containment, respiratory protection and industrial hygiene monitoring. The majority of material safety data sheets (MSDS) or safety data sheets (SDS) are inadequate in warning of the hazards of dimethyl fumarate. This occupational exposure limit monograph contains the most current health and safety information regarding dimethyl fumarate.
In addition, this OEL Fastrac monograph also contains the acceptable daily exposure (ADE) value.
Click on the following link for more information on the OEL Fastrac monograph for Dimethyl Fumarate with instant download.
Affygility Solutions’ President and CEO, Dean Calhoun, CIH will be presenting “The Future of Pharmaceutical Manufacturing – the Next 100 Years,” during the American Association of Pharmaceutical Scientists (AAPS) annual convention. Mr. Calhoun’s presentation will be on November 4th, 2014 at 2:00 p.m. at the Pharmatek booth (booth no. 3319). For more information on all the other exciting activities that Pharmatek is providing, go to Pharmatek’s AAPS webpage.
Mr. Calhoun will be available for one-on-one meetings immediately following his presentation. If you would like to discuss potent compound safety, exposure control banding, or qualitative risk assessment of pharmaceutical manufacturing operations please send a meeting request via the contact us form on the Affygility Solutions’ website.